

ANALYSIS OF THE PHARMACEUTICAL MARKET ANTHELMINTIC DRUGS

Nizhnik Z.M., Nehoda T.S., Nizhenkovskiy O.I.
Bogomolets National Medical University, Kiev, Ukraine

Over the past 5 years, there has been a clear upward trend in the incidence of invasive aetiology, in particular, helminthiasis.

Among the main 250 species of helminths in Ukraine, more than 25 pathogens have been identified, mainly of the digestive system. The reasons for this phenomenon are active population migration, including tourism, as well as the ability of helminth eggs, cysts and larvae to persist in the environment for a long time and pose a threat of new infections.

According to the WHO, about 4.5 million people worldwide are affected by parasitic diseases. According to official statistics, 25-30 of the 342 known species of helminths are widespread in Ukraine. Among them, 74 % are enterobiasis, 23 % are hookworm, 3 % are trichocephalosis, and up to 0,5 % are other helminths.

The purpose of our study is to analyse the range of albendazole-based medicines as the most common anthelmintic.

The anthelmintic market research was conducted on the example of albendazole APIs, as this substance is the most commonly used anthelmintic. The following anthelmintics are available on the Ukrainian pharmaceutical market: praziquantel, piperazine, pyrantel, levamisole, pyrvinium, mebendazole and albendazole. These drugs are used to treat.

- trematodoses - praziquantel;
- nematodes - mebendazole, albendazole, pyrantel, piperazine, levamisole;
- dracunculiasis - metronidazole;
- cestodoses - praziquantel and albendazole.

The main method of treating echinococcosis and cysticercosis is surgical, and albendazole is used as an adjuvant.

Albendazole stands out among most antiparasitic drugs. The drug is highly effective in most helminthiasis, has a broad spectrum of anthelmintic action and a high safety profile. Features of pharmacokinetics and pharmacodynamics, the spectrum of anthelmintic action of albendazole, which give it advantages over other anthelmintics

As of December 2023, there are 17 albendazole-based medicines in the State Register of Medicines of Ukraine.

The existing range of albendazole-based dosage forms includes tablets (24%), chewable tablets (35%), coated tablets (6%), suspensions (24%) and substance (12%).

Albendazole-based medicines are mainly supplied to the domestic pharmaceutical market by manufacturers in Ukraine and India.

Thus, the development of effective and economically affordable anthelmintics is an urgent task for pharmacy.